IMNM
Price
$18.77Alerts
Change
+$0.07 (+0.37%)
Updated
Nov 13 closing price
Capitalization
2.13B
129 days until earnings call
Intraday BUY SELL Signals
IVA
Price
$3.68Alerts
Change
-$0.20 (-5.15%)
Updated
Nov 13 closing price
Capitalization
897.69M
7 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

IMNM vs IVA

IMNM vs IVA Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
IMNM vs. IVA commentary
Nov 16, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IMNM is a Hold and IVA is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for IMNM with price predictions
Nov 13, 2026

IMNM's RSI Indicator ascends from oversold territory

The RSI Oscillator for IMNM moved out of oversold territory on October 20, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 34 similar instances when the indicator left oversold territory. In 31 of the 34 cases the stock moved higher. This puts the odds of a move higher at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

The Momentum Indicator moved above the 0 level on November 11, 2026. You may want to consider a long position or call options on IMNM as a result. In 68 of 76 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 89%.

The Moving Average Convergence Divergence (MACD) for IMNM just turned positive on October 22, 2026. Looking at past instances where IMNM's MACD turned positive, the stock continued to rise in 36 of 45 cases over the following month. The odds of a continued upward trend are 80%.

Following a +8.13% 3-day Advance, the price is estimated to grow further. Considering data from situations where IMNM advanced for three days, in 236 of 286 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.

The Aroon Indicator entered an Uptrend today. In 156 of 189 cases where IMNM Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 83%.

Bearish Trend Analysis

The 50-day moving average for IMNM moved below the 200-day moving average on October 30, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMNM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.

IMNM broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 25 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating steady price growth. IMNM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 70 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.047) is normal, around the industry mean (3.498). P/E Ratio (-7.395) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (625.000) is also within normal values, averaging (440.869).

The Tickeron Profit vs. Risk Rating rating for this company is 97 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMNM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

A.I.Advisor
a Summary for IVA with price predictions
Nov 13, 2026

IVA's RSI Indicator leaves overbought zone

The 10-day RSI Oscillator for IVA moved out of overbought territory on November 04, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 instances where the indicator moved out of the overbought zone. In 20 of the 22 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 49 of 53 cases where IVA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IVA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 21, 2026. You may want to consider a long position or call options on IVA as a result. In 79 of 97 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.

The Moving Average Convergence Divergence (MACD) for IVA just turned positive on October 20, 2026. Looking at past instances where IVA's MACD turned positive, the stock continued to rise in 28 of 38 cases over the following month. The odds of a continued upward trend are 74%.

IVA moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for IVA crossed bullishly above the 50-day moving average on November 05, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 15 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 88%.

Following a +4.43% 3-day Advance, the price is estimated to grow further. Considering data from situations where IVA advanced for three days, in 175 of 232 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.

IVA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 115 of 158 cases where IVA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 73%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 27 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 52 (best 1 - 100 worst), indicating steady price growth. IVA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 99 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.215) is normal, around the industry mean (3.498). P/E Ratio (-7.170) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (136.986) is also within normal values, averaging (440.869).

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IVA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
IMNM vs IVA: Fundamental Ratings
IMNM
IVA
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
70
Overvalued
99
Overvalued
PROFIT vs RISK RATING
1..100
97100
SMR RATING
1..100
98100
PRICE GROWTH RATING
1..100
5852
P/E GROWTH RATING
1..100
2527
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IMNM's Valuation (70) in the null industry is in the same range as IVA (99). This means that IMNM’s stock grew similarly to IVA’s over the last 12 months.

IMNM's Profit vs Risk Rating (97) in the null industry is in the same range as IVA (100). This means that IMNM’s stock grew similarly to IVA’s over the last 12 months.

IMNM's SMR Rating (98) in the null industry is in the same range as IVA (100). This means that IMNM’s stock grew similarly to IVA’s over the last 12 months.

IVA's Price Growth Rating (52) in the null industry is in the same range as IMNM (58). This means that IVA’s stock grew similarly to IMNM’s over the last 12 months.

IMNM's P/E Growth Rating (25) in the null industry is in the same range as IVA (27). This means that IMNM’s stock grew similarly to IVA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IMNMIVA
RSI
ODDS (%)
Bullish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
83%
Bearish Trend 3 days ago
90%
Momentum
ODDS (%)
Bullish Trend 3 days ago
89%
Bullish Trend 3 days ago
81%
MACD
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 3 days ago
74%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
85%
Bearish Trend 3 days ago
87%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
83%
Bullish Trend 3 days ago
77%
Advances
ODDS (%)
Bullish Trend 7 days ago
83%
Bullish Trend 5 days ago
75%
Declines
ODDS (%)
Bearish Trend 11 days ago
86%
Bearish Trend 3 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
86%
Bullish Trend 4 days ago
82%
Aroon
ODDS (%)
Bullish Trend 3 days ago
83%
Bullish Trend 3 days ago
73%
COMPARISON
Comparison
Nov 16, 2026
Stock price -- (IMNM: $18.77 vs. IVA: $3.68)
Brand notoriety: IMNM and IVA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IMNM: 59% vs. IVA: 112%
Market capitalization -- IMNM: $2.13B vs. IVA: $897.69M
IMNM [@Biotechnology] is valued at $2.13B. IVA’s [@Biotechnology] market capitalization is $897.69M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IMNM’s FA Score shows that 1 FA rating(s) are green while IVA’s FA Score has 1 green FA rating(s).

  • IMNM’s FA Score: 1 green, 4 red.
  • IVA’s FA Score: 1 green, 4 red.
According to our system of comparison, both IMNM and IVA are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IMNM’s TA Score shows that 6 TA indicator(s) are bullish while IVA’s TA Score has 7 bullish TA indicator(s).

  • IMNM’s TA Score: 6 bullish, 3 bearish.
  • IVA’s TA Score: 7 bullish, 3 bearish.
According to our system of comparison, IVA is a better buy in the short-term than IMNM.

Price Growth

IMNM (@Biotechnology) experienced а +0.32% price change this week, while IVA (@Biotechnology) price change was -3.16% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.38%. For the same industry, the average monthly price growth was -5.88%, and the average quarterly price growth was -18.27%.

Reported Earning Dates

IMNM is expected to report earnings on Mar 25, 2027.

IVA is expected to report earnings on Nov 23, 2026.

Industries' Descriptions

@Biotechnology (-3.38% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

IMNM and

Correlation & Price change

A.I.dvisor indicates that over the last year, IMNM has been loosely correlated with KYTX. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if IMNM jumps, then KYTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IMNM
1D Price
Change %
IMNM100%
+0.37%
KYTX - IMNM
60%
Loosely correlated
+0.40%
SLDB - IMNM
53%
Loosely correlated
-2.29%
EDIT - IMNM
52%
Loosely correlated
+1.40%
MGTX - IMNM
51%
Loosely correlated
+4.44%
LXEO - IMNM
51%
Loosely correlated
-1.37%
More

IVA and

Correlation & Price change

A.I.dvisor indicates that over the last year, IVA has been loosely correlated with SLDB. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if IVA jumps, then SLDB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IVA
1D Price
Change %
IVA100%
-5.15%
SLDB - IVA
41%
Loosely correlated
-2.29%
IMNM - IVA
39%
Loosely correlated
+0.37%
MGTX - IVA
38%
Loosely correlated
+4.44%
DNTH - IVA
38%
Loosely correlated
-0.72%
PTGX - IVA
38%
Loosely correlated
-2.55%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
EIX60.180.19
+0.32%
Edison International
NMTC0.75N/A
-0.31%
NeuroOne Medical Technologies Corporation
BCAL21.97-0.08
-0.36%
California BanCorp
IEP4.74-0.12
-2.47%
Icahn Enterprises LP
CAN0.15-0.01
-3.97%
Canaan